A new UCLA-led study suggests that advanced genome editing technology could be used as a one-time treatment for the rare and deadly genetic disease CD3 delta severe combined immunodeficiency. The ...
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. “The granting of this patent on first-in-class formulation technology allows us to work on ...
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, June 19, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results